Physicians' Academy for Cardiovascular Education

What is the situation one year after the presentation about the CANTOS trial?

CSI Munich

10' education - Aug. 26, 2018 - Munich, Germany - Prof. Paul Ridker, MD - Boston, MA, USA

Video navigation menu

  • Implementation of canakinumab in daily practice 0:52
  • Distinction responders and non-responders in CANTOS trial 2:51
  • Dosis-dependent effect of canakinumab 4:44
  • Cost-effectiveness of canakinumab 5:17
  • IL-1beta inhibition in primary prevention 8:24
  • Vision about canakinumab 9:33

Educational information

In the Cardiovascular Scene Investigation (CSI) series, investigators from Utrecht report at the ESC congress, from perspective of young investigators. They put a question to researchers about presented study results.


Prof. Paul Ridker, MD - Brigham and Women's hospital, Boston, MA, USA


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: